{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:00:39Z","timestamp":1785222039255,"version":"3.55.0"},"reference-count":46,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0088","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:32:03Z","timestamp":1785220323000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac Amyloidosis: Pathogenesis, diagnosis, and treatment"],"prefix":"10.3238","author":[{"given":"Sophie","family":"Beckmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Haghikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazha","family":"Hamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"El-Battrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"10.3238\/arztebl.m2026.0088_ref1","doi-asserted-by":"crossref","unstructured":"Griffin JM, Rosenblum H, Maurer MS: Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res 2021; 128: 1554\u201375.","DOI":"10.1161\/CIRCRESAHA.121.318187"},{"key":"10.3238\/arztebl.m2026.0088_ref2","doi-asserted-by":"crossref","unstructured":"Ney S, Ihle P, Ruhnke T, et al.: Epidemiology of cardiac amyloidosis in Germany: A retrospective analysis from 2009 to 2018. Clin Res Cardiol 2023; 112: 401\u20138.","DOI":"10.1007\/s00392-022-02114-y"},{"key":"10.3238\/arztebl.m2026.0088_ref3","unstructured":"GBE\u2014Gesundheitsberichterstattung des Bundes: Diagnosedaten der Krankenh\u00e4user nach Behandlungsort (ICD10\u20134-Steller, ab 2000). www.gbe-bund.de:443\/gbe\/isgbe.archiv?p_indnr=702&p_archiv_id=10055943&p_sprache=D&p_action=A (last accessed on 27 February 2026)."},{"key":"10.3238\/arztebl.m2026.0088_ref4","doi-asserted-by":"crossref","unstructured":"Aimo A, Merlo M, Porcari A, et al.: Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail 2022; 24: 2342\u201351.","DOI":"10.1002\/ejhf.2532"},{"key":"10.3238\/arztebl.m2026.0088_ref5","doi-asserted-by":"crossref","unstructured":"Vogel J, Jura S, Settelmeier S, et al.: Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real-world data analysis. ESC Heart Fail 2025; 12: 2969\u201375.","DOI":"10.1002\/ehf2.15311"},{"key":"10.3238\/arztebl.m2026.0088_ref6","unstructured":"Sch\u00f6nland SO: Fortschritte in der Diagnostik und Therapie der Amyloidosen. Dtsch Arztebl 2006; 103: A 2237\u201344."},{"key":"10.3238\/arztebl.m2026.0088_ref7","doi-asserted-by":"crossref","unstructured":"Ihne S, Morbach C, Sommer C, Geier A, Knop S, St\u00f6rk S:Amyloidosis\u2014the diagnosis and treatment of an underdiagnosed disease. Dtsch Arztebl Int 2020; 117: 159\u201366.","DOI":"10.3238\/arztebl.2020.0159"},{"key":"10.3238\/arztebl.m2026.0088_ref8","doi-asserted-by":"crossref","unstructured":"Yilmaz A, Bauersachs J, Bengel F, et al.: Diagnosis and treatment of cardiac amyloidosis: Position statement of the German Cardiac Society (DGK). Clin Res Cardiol 2021; 110: 479\u2013506.","DOI":"10.1007\/s00392-020-01799-3"},{"key":"10.3238\/arztebl.m2026.0088_ref9","doi-asserted-by":"crossref","unstructured":"Pfister R, Hagenacker T, Heemann U, et al.: Versorgung von Patienten mit kardialer Amyloidose: Konsensuspapier der Deutschen Gesellschaft f\u00fcr Kardiologie\u2014Herz- und Kreislaufforschung e. V. (DGK), AG 40 Onkologische Kardiologie, und der Deutschen Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie e. V. (DGHO), der Deutschen Gesellschaft f\u00fcr Neurologie e. V. (DGN) und der Deutschen Gesellschaft f\u00fcr Nephrologie e. V. (DGfN). Kardiologie 2024; 18: 36\u201343.","DOI":"10.1007\/s12181-023-00653-w"},{"key":"10.3238\/arztebl.m2026.0088_ref10","doi-asserted-by":"crossref","unstructured":"Nijst P, Tang WW: Recent advances in the diagnosis and management of amyloid cardiomyopathy. Fac Rev 2021; 10: 31.","DOI":"10.12703\/r\/10-31"},{"key":"10.3238\/arztebl.m2026.0088_ref11","doi-asserted-by":"crossref","unstructured":"Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al.: Prevalence and clinical outcomes of transthyretin amyloidosis: A systematic review and meta-analysis. Eur J Heart Fail 2022; 24: 1677\u201396.","DOI":"10.1002\/ejhf.2589"},{"key":"10.3238\/arztebl.m2026.0088_ref12","doi-asserted-by":"crossref","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF, et al.: Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018; 57: 829\u201337.","DOI":"10.1002\/mus.26034"},{"key":"10.3238\/arztebl.m2026.0088_ref13","doi-asserted-by":"crossref","unstructured":"Rosenzweig M, Landau H: Light chain (AL) amyloidosis: Update on diagnosis and management. J Hematol Oncol 2011; 4: 47.","DOI":"10.1186\/1756-8722-4-47"},{"key":"10.3238\/arztebl.m2026.0088_ref14","doi-asserted-by":"crossref","unstructured":"Ablasser K, Verheyen N, Glantschnig T, Agnetti G, Rainer PP: Unfolding cardiac amyloidosis-from pathophysiology to cure. Curr Med Chem 2019; 26: 2865\u201378.","DOI":"10.2174\/0929867325666180104153338"},{"key":"10.3238\/arztebl.m2026.0088_ref15","doi-asserted-by":"crossref","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al.: Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30: 989\u201395.","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"10.3238\/arztebl.m2026.0088_ref16","doi-asserted-by":"crossref","unstructured":"Vergaro G, Castiglione V, Aimo A, et al.: N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis. Eur J Heart Fail 2023; 25: 335\u201346.","DOI":"10.1002\/ejhf.2769"},{"key":"10.3238\/arztebl.m2026.0088_ref17","doi-asserted-by":"crossref","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al.: 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 2023; 44: 3503\u2013626.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"10.3238\/arztebl.m2026.0088_ref18","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.: Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021; 42: 1554\u201368.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"10.3238\/arztebl.m2026.0088_ref19","doi-asserted-by":"crossref","unstructured":"Binder C, Duca F, Binder T, et al.: Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clin Res Cardiol 2021; 110: 532\u201343.","DOI":"10.1007\/s00392-020-01698-7"},{"key":"10.3238\/arztebl.m2026.0088_ref20","doi-asserted-by":"crossref","unstructured":"Klein AL, Hatle LK, Burstow DJ, et al.: Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1989; 13: 1017\u201326.","DOI":"10.1016\/0735-1097(89)90254-4"},{"key":"10.3238\/arztebl.m2026.0088_ref21","doi-asserted-by":"crossref","unstructured":"Phelan D, Collier P, Thavendiranathan P, et al.: Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442\u20138.","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"10.3238\/arztebl.m2026.0088_ref22","doi-asserted-by":"crossref","unstructured":"Fontana M, Banypersad SM, Treibel TA, et al.: Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 2014; 7: 157\u201365.","DOI":"10.1016\/j.jcmg.2013.10.008"},{"key":"10.3238\/arztebl.m2026.0088_ref23","doi-asserted-by":"crossref","unstructured":"Perugini E, Guidalotti PL, Salvi F, et al.: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076\u201384.","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"10.3238\/arztebl.m2026.0088_ref24","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404\u201312.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"10.3238\/arztebl.m2026.0088_ref25","doi-asserted-by":"crossref","unstructured":"Witteles RM, Bokhari S, Damy T, et al.: Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019; 7: 709\u201316.","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"10.3238\/arztebl.m2026.0088_ref26","doi-asserted-by":"crossref","unstructured":"Bhatt K, Delgado DH, Khella S, et al.: Hereditary transthyretin amyloidosis in patients referred to a genetic testing program. J Am Heart Assoc 2024; 13: e033770.","DOI":"10.1161\/JAHA.123.033770"},{"key":"10.3238\/arztebl.m2026.0088_ref27","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al.: 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2023; 44: 3627\u201339.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"10.3238\/arztebl.m2026.0088_ref28","doi-asserted-by":"crossref","unstructured":"Ioannou A, Massa P, Patel RK, et al.: Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J 2023; 44: 2893\u2013907.","DOI":"10.1093\/eurheartj\/ehad347"},{"key":"10.3238\/arztebl.m2026.0088_ref29","doi-asserted-by":"crossref","unstructured":"Porcari A, Cappelli F, Nitsche C, et al.: SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2024; 83: 2411\u201322.","DOI":"10.1016\/j.jacc.2024.03.429"},{"key":"10.3238\/arztebl.m2026.0088_ref30","doi-asserted-by":"crossref","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC: Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020; 6: 351\u201361.","DOI":"10.1016\/j.jacep.2020.01.004"},{"key":"10.3238\/arztebl.m2026.0088_ref31","unstructured":"Pfizer Pharma GmbH (als \u00f6rtlicher Vertreter des Zulassungsinhabers Pfizer Europe MA EEIG): Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V. Tafamidis (Vyndaqel\u00ae). Modul 2: Allgemeine Angaben zum Arzneimittel, zugelassene Anwendungsgebiete. Stand: 21.02.2020. www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/524\/#dossier (last accessed on 8 February 2026)."},{"key":"10.3238\/arztebl.m2026.0088_ref32","unstructured":"Europ\u00e4ische Kommission: Zulassung von Acoramidis\u2014Anhang I: Zusammenfassung der Merkmale des Arzneimittels (EU\/1\/24\/1760). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250210165087\/anx_165087_de.pdf (last accessed on 8 February 2026)."},{"key":"10.3238\/arztebl.m2026.0088_ref33","unstructured":"Europ\u00e4ische Kommission: Zulassung von Amvuttra\u2014Anhang I: Zusammenfassung der Merkmale des Arzneimittels. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250605166961\/anx_166961_de.pdf (last accessed on 25 April 2026)."},{"key":"10.3238\/arztebl.m2026.0088_ref34","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007\u201316.","DOI":"10.1056\/NEJMoa1805689"},{"key":"10.3238\/arztebl.m2026.0088_ref35","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al.: Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med 2024; 390: 132\u201342.","DOI":"10.1056\/NEJMoa2305434"},{"key":"10.3238\/arztebl.m2026.0088_ref36","doi-asserted-by":"crossref","unstructured":"Judge DP, Alexander KM, Cappelli F, et al.: Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2025; 85: 1003\u201314.","DOI":"10.1016\/j.jacc.2024.11.042"},{"key":"10.3238\/arztebl.m2026.0088_ref37","doi-asserted-by":"crossref","unstructured":"Fontana M, Berk JL, Gillmore JD, et al.: Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med 2025; 392: 33\u201344.","DOI":"10.1056\/NEJMe2410890"},{"key":"10.3238\/arztebl.m2026.0088_ref38","doi-asserted-by":"crossref","unstructured":"Terentes-Printzios D, Koilakou ME, Alexiou P, et al.: Serum transthyretin as prognostic biomarker for cardiovascular events and mortality. A systematic review and meta-analysis. JACC Adv 2025; 4: 102208.","DOI":"10.1016\/j.jacadv.2025.102208"},{"key":"10.3238\/arztebl.m2026.0088_ref39","doi-asserted-by":"crossref","unstructured":"Mori Y, Kenzaka T: Systemic amyloid light chain amyloidosis with repeated syncope due to severe orthostatic hypotension caused by autonomic Neuropathy: A case report. Cureus 2024; 16: e73320.","DOI":"10.7759\/cureus.73320"},{"key":"10.3238\/arztebl.m2026.0088_ref40","doi-asserted-by":"crossref","unstructured":"Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S: Peripheral nerve Involvement in primary systemic AL amyloidosis: A clinical and electrophysiological study. Eur J Neurol 2011; 18: 604\u201310.","DOI":"10.1111\/j.1468-1331.2010.03215.x"},{"key":"10.3238\/arztebl.m2026.0088_ref41","doi-asserted-by":"crossref","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS: Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol.2019; 73: 2872\u201391.","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"10.3238\/arztebl.m2026.0088_ref42","doi-asserted-by":"crossref","unstructured":"aus dem Siepen F, Hein S, Prestel S, et al.: Carpal tunnel syndrome and spinal canal stenosis: Harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 2019; 108: 1324\u201330.","DOI":"10.1007\/s00392-019-01467-1"},{"key":"10.3238\/arztebl.m2026.0088_ref43","doi-asserted-by":"crossref","unstructured":"Visram A, Al Saleh AS, Parmar H, et al.: Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer J 2020; 10: 124.","DOI":"10.1038\/s41408-020-00391-2"},{"key":"10.3238\/arztebl.m2026.0088_ref44","doi-asserted-by":"crossref","unstructured":"Teresi L, Trimarchi G, Liotta P, et al.: Electrocardiographic patterns and arrhythmias in cardiac amyloidosis: From diagnosis to therapeutic management\u2014a narrative review. J Clin Med 2024; 13: 5588.","DOI":"10.3390\/jcm13185588"},{"key":"10.3238\/arztebl.m2026.0088_ref45","doi-asserted-by":"crossref","unstructured":"Nagy D, R\u00e9v\u00e9sz K, Pesk\u00f3 G, et al.: Cardiac amyloidosis with normal wall thickness: prevalence, clinical characteristics and outcome in a retrospective analysis. Biomedicines 2022; 10: 1765.","DOI":"10.3390\/biomedicines10071765"},{"key":"10.3238\/arztebl.m2026.0088_ref46","doi-asserted-by":"crossref","unstructured":"Maurer MS, Kale P, Fontana M, et al.: Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023; 389: 1553\u201365.","DOI":"10.1056\/NEJMoa2300757"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T06:32:18Z","timestamp":1785220338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":46,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0088","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}